Get the Stockscreener App
0.1297
2.92%
-0.0039
After Hours:
.13
0.0003
+0.23%
Glucotrack Inc stock is traded at $0.1297, with a volume of 1.47M.
It is down -2.92% in the last 24 hours and down -24.33% over the past month.
GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on proven healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.
See More
Previous Close:
$0.1336
Open:
$0.1343
24h Volume:
1.47M
Relative Volume:
0.28
Market Cap:
$3.71M
Revenue:
-
Net Income/Loss:
$-8.74M
P/E Ratio:
-0.0633
EPS:
-2.05
Net Cash Flow:
$-8.25M
1W Performance:
-2.70%
1M Performance:
-24.33%
6M Performance:
-97.33%
1Y Performance:
-99.69%
1-Day Range:
$0.1231
$0.1343
1-Week Range:
$0.1231
$0.1398
52-Week Range:
$0.1231
$62.60
Glucotrack Inc Stock (GCTK) Company Profile
Name
Glucotrack Inc
Sector
Industry
Phone
972 (8) 675-7878
Address
301 RT 17 NORTH, RUTHERFORD
Compare GCTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GCTK
Glucotrack Inc
|
0.1297 | 3.82M | 0 | -8.74M | -8.25M | -2.05 |
|
ISRG
Intuitive Surgical Inc
|
552.34 | 193.38B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
172.59 | 49.12B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
85.94 | 42.79B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
244.79 | 35.61B | 5.02B | 1.31B | 1.56B | 8.91 |
|
BAX
Baxter International Inc
|
30.50 | 15.46B | 11.89B | -560.00M | 191.00M | -1.10 |
Glucotrack Inc Stock (GCTK) Latest News
GCTK stock plunges to 52-week low, hits $0.13 - Investing.com Australia
GCTK stock plunges to 52-week low, hits $0.13 By Investing.com - Investing.com UK
Upcoming Benzinga Webinar With Glucotrack To Discuss The Potential Of Its Innovative CBGM Technology To Transform Diabetes Care And Patient Lives - FinancialContent
Glucotrack appoints new board member with diabetes tech expertise By Investing.com - Investing.com South Africa
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD - The Manila Times
GCTKGlucotrack Latest Stock News & Market Updates - Stock Titan
GlucoTrack (NASDAQ:GCTK) Trading Down 0.2% – Time to Sell? - Defense World
GlucoTrack Approves Key Proposals at Annual Meeting - TipRanks
GCTK stock plunges to 52-week low, touches $0.13 - Investing.com Australia
GCTK stock plunges to 52-week low, touches $0.13 By Investing.com - Investing.com Nigeria
GlucoTrack Establishes Patient Advisory Board for CBGM - TipRanks
Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology Development - The Manila Times
Glucotrack, Inc. Forms Patient Advisory Board to Enhance Development of Continuous Blood Glucose Monitor - Nasdaq
Groundbreaking 3-Year Implantable Glucose Monitor Gets Patient-Led Development at Glucotrack - Stock Titan
Glucotrack Reports Q1 2025 Financial Results and Progress - TipRanks
Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Innovative Continuous Blood Glucose Monitor Shows Promise in First Human Trial - citybuzz -
GlucoTrack Reports Q1 2025 Financial Results and Progress - TipRanks
Glucotrack, Inc. SEC 10-Q Report - TradingView
Glucotrack, Inc. Advances Continuous Blood Glucose Monitoring Technology with Clinical Study Initiation in Australia by Q3 2025 - Nasdaq
Glucotrack Reports First Quarter 2025 Financial Results And Recent Corporate Highlights - marketscreener.com
Breakthrough: Glucotrack's Implantable Diabetes Monitor Hits Clinical Milestone, FDA Decision Expected Q4 - Stock Titan
Glucotrack gains HREC approval for clinical study of CBGM device - Yahoo Finance
First-In-Human Study In The Bag, Glucotrack Gears Up For Long-Term Trial Of Potentially Groundbreaking Continuous Blood Glucose Monitor For Diabetes Patients - FinancialContent
Certain Options of GlucoTrack, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2025. - marketscreener.com
Certain Common Stock of GlucoTrack, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2025. - marketscreener.com
GlucoTrack Gains Approval for Long-Term Clinical Study - TipRanks
Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor - The Manila Times
Geode Capital Management LLC Increases Stock Holdings in GlucoTrack, Inc. (NASDAQ:GCTK) - Defense World
GlucoTrack Inc (GCTK) can make a big difference with a little luck - Sete News
Medtech CEO Shares Lessons From FIH Implantable Glucose Monitor Trial - Clinical Leader
GlucoTrack Releases Investor Presentation on April 29 - TipRanks
GlucoTrack Inc (NASDAQ:GCTK) stock crossing the finish line today - uspostnews.com
Can GlucoTrack Inc Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Now Is The Time To Build A Position In GlucoTrack Inc (NASDAQ:GCTK) - Marketing Sentinel
Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights - ADVFN
It makes sense and dollars to buy GlucoTrack Inc (GCTK) stock - Sete News
Pre-market Movers: OPTN, WINT, AKBA, GCTK... - RTTNews
GlucoTrack Joins EU Bionic Pancreas Initiative - TipRanks
Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas - The Manila Times
Major Breakthrough: Glucotrack Selected for EU's Revolutionary Bionic Pancreas Project - Stock Titan
Glucotrack to bring CBGM to bionic pancreas initiative in Europe - Drug Delivery Business
Investing in GlucoTrack Inc (GCTK) might be an excellent idea, but the stock is currently overvalued/undervalued - uspostnews.com
GCTK stock plunges to 52-week low of $0.15 amid market turmoil By Investing.com - Investing.com South Africa
GCTK stock plunges to 52-week low of $0.15 amid market turmoil - Investing.com India
Glucotrack faces Nasdaq delisting over share price rule - Investing.com Australia
Glucotrack faces Nasdaq delisting over share price rule By Investing.com - Investing.com South Africa
Glucotrack partners with OneTwo Analytics for AI diabetes data analysis By Investing.com - Investing.com South Africa
6 Alternatives to Apple’s Non-Invasive Glucose Monitoring You Can Try Now - The Mac Observer
GlucoTrack Partners with OneTwo Analytics for AI-Driven Insights - TipRanks
Glucotrack partners with OneTwo Analytics for AI diabetes data analysis - Investing.com Australia
Glucotrack Inc Stock (GCTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.66%
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):